Tlr3 agonist for use for inducing apoptosis in senescent cancer cells
AssigneesCentre Leon Berard, Institut National De La Sante Et De La Recherche Medicale (Inserm), Centre National De La Recherche Scientifique, Universite Claude Bernard Lyon 1, Hospices Civils De Lyon
InventorsSerge LEBECQUE, Toufic RENNO, Béatrice VANBERVLIET, Yann ESTORNES
Life of this patent
Estimating the term…
Abstract
The present invention relates to a TLR3 agonist for use for inducing apoptosis in senescent cancer cells, in particular to a TLR3 agonist for use as a medicament for inducing apoptosis in senescent cancer cells. In particular, it relates to a TLR3 agonist for use for the treatment of cancer, optionally in combination with a chemotherapeutic agent or with radiotherapy. It further relates to a pharmaceutical composition comprising a TLR3 agonist and a chemotherapeutic agent.
Claims15
1-12. (canceled)
A method for inducing apoptosis in senescent cancer cells, comprising the administration, in a patient in need thereof, of a therapeutically effective amount of a TLR3 agonist.
A pharmaceutical composition comprising a TLR3 agonist and a chemotherapeutic agent.
Dependencies are inferred from the claim text.